1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Pulmory Arterial Hypertension: Executive Summary
2.1 PAH Market Will Exhibit Moderate Growth Between 2019 and 2029
2.2 Sotatercept Has the Potential to Become a Blockbuster Therapy and Address an Unmet Need in PAH
2.3 Reformulation of Existing Drugs Will Continue to Domite the PAH Pipeline
2.4 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for PAH (2019-2029)
5.6 Discussion

6 Disease Magement
6.1 Diagnosis and Treatment Overview
6.2 Clinical Practice
6.3 Overview of Treatment Guidelines
6.4 US
6.5 5EU
6.6 Japan

7 Competitive Assessment
7.1 Overview

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Curative or Stabilizing Therapeutics Targeting a Novel, Fourth Pathway
8.3 Improved Drug Administration and Side Effects
8.4 Improved Clinical Trial Design and Slowing Disease Progression
8.5 Drugs to Prevent Right Heart Failure

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development

10 Current and Future Players

11 Market Outlook

12 Appendix